Clinical significance of cathepsin D assay in breast cancer tissues.
Cathepsin D was assayed in 74 primary breast cancer specimens by enzyme immunoassay (EIA) and immunohistochemical assay (ICA). Of the 74 specimens, 38 (51.4%) were scored positive by ICA, and 25 (33.8%) were scored positive by EIA. The coincidence rate between ICA and EIA was 71.6% (53/74). There was no significant correlation between cathepsin D and menopausal status, tumor size, number size, number of metastatic lymph nodes, histological type of the tumor, or steroid receptor status. Cathepsin D status designated by EIA or ICA predicted neither disease-free survival (DFS) nor overall survival (OAS). Subject analysis with estrogen receptor, menopausal, and lymph node status revealed no association between cathepsin D and DFS or OAS. Therefore, cathepsin D is not an independent prognostic factor in breast cancer.
Itoh
Y
Y
Second Department of Surgery, Nagoya City University Medical School, Japan.
Kobayashi
S
S
Iwase
H
H
Yamashita
H
H
Kuzushima
T
T
Iwata
H
H
Yamashita
T
T
Naitoh
A
A
Itoh
K
K
Masaoka
A
A
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000201:enzymology*; D002402:Cathepsin D / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis
D011960:Receptors, Estrogen; D002402:Cathepsin D